Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $89

Benzinga Newsdesk www.benzinga.com Positive 65.1%

Neg 0% Neu 0% Pos 65.1%

Morgan Stanley analyst Terence Flynn maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from $39 to $89.